Microba Announces Landmark GI Study Results From Over 4,600 Patients
Article content
Article content
BRISBANE, Australia — Microba Life Sciences Limited (ASX: MAP) ('Microba' or the 'Company'), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results.
Article content
'MetaXplore is a powerful addition to the diagnostic toolbox for patients with persistent gastrointestinal symptoms…' Commented Associate Professor Graham Radford-Smith.
These results highlight the clinical value of MetaXplore test results in advancing outcomes for patients with chronic lower gastrointestinal disorders, highlighting the potential to reshape clinical management of these conditions and set a new standard of care. An in-depth analysis of billing and claims data for MetaXplore target patient populations, has estimated an addressable population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia.
Article content
Analysis conducted by Microba of 4,616 MetaXplore™ GI Plus patients test results from Australia revealed that 71.4% (3,295) of reports identified actionable results.
Article content
41.9% (1,932) of reports showed abnormal microbiome markers linked to gastrointestinal health, including 7% that were positive for a pathogen species that can cause GI infection. These abnormal microbiome markers can be addressed via evidence-based targeted nutritional or lifestyle changes, or antimicrobial therapy (antibiotics) when a pathogen is identified.
9.9% (459) of reports tested positive for a gastrointestinal marker (e.g. inflammation, pancreatic insufficiency, or faecal occult blood), prompting further diagnostic workup and supporting management of conditions such as inflammatory bowel disease (IBD), colorectal cancer, or pancreatic insufficiency via pharmacological treatment including biologics
19.6% (904) of reports tested positive for multiple markers (microbiome and gastrointestinal), addressed via a personalised mix of pharmacological, nutritional and lifestyle modification strategies
Article content
These results demonstrate how the MetaXplore test provides critical new insights to enable clinicians to apply personalised, multi-dimensional treatment plans to support the clinical management of patients with chronic and functional lower gastrointestinal disorders. In cases where no significant findings were identified, the results can help clinicians to rule out and narrow potential causes of the patients' gastrointestinal symptoms, and may suggest psychological or neurological contributors to symptoms which empower additional clinical pathways. This study is ongoing, supports the integration of MetaXplore testing into standard care protocols, and is expected to be published in peer-reviewed journals.
Article content
A separate study of 84 patients by Microba who received MetaXplore-guided care found that 65.5% reported health improvements after following their clinician's recommendations:
Article content
These preliminary results highlight how the MetaXplore test results and personalised, targeted interventions improve patient outcomes. This initial patient survey data demonstrates the relationship between MetaXplore positive test results and improved patient outcomes, supporting the clinical impact Microba is seeing with clinicians and patients, and setting up for larger planned studies measuring patient outcomes.
Article content
Associate Professor Graham Radford-Smith, a leading gastroenterologist and expert in functional GI disorders, is currently working with Microba on a clinical utility study of MetaXplore™ in his practice. He commented:
Article content
'MetaXplore is a powerful addition to the diagnostic toolbox for patients with persistent gastrointestinal symptoms. It enables me to objectively identify microbiome dysbiosis, evaluate dietary quality, and direct patients toward evidence-based nutritional strategies. Importantly, it helps differentiate patients with normal GI and microbial profiles who may benefit from psychological support rather than further invasive testing or pharmacological escalation.'
Article content
An in-depth analysis of billing and claims data for MetaXplore target patient populations, estimated an addressable population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia 1. This population consists of patients with chronic diarrhoea or non-specific abdominal symptoms such as pain, bloating and constipation, including patients characterised with Irritable Bowel Syndrome (IBS) or diagnosed with Inflammatory Bowel Disease (IBD). The current standard of care for these patients is leading to an estimated 50% of patients not getting a resolution to their symptoms 2, necessitating a radical advancement in the tools available to support these patients and improve outcomes. MetaXplore™ is supporting clinicians to manage and improve outcomes for these patients through a comprehensive test that can:
Article content
Assess structural and functional abnormalities in the microbiome
Detect overlooked harmful gut bacteria (pathogens), inflammatory or insufficiency markers
Identify evidence based, personalised pharmacological, nutritional and lifestyle modification strategies
Support patient motivation and adherence to pharmacological, nutritional and lifestyle modifications
May support identification of cases where mental health support may be appropriate
Article content
As the burden of chronic digestive disorders continues to grow, MetaXplore offers a scalable, evidence-based new solution to evaluate and clinically manage GI dysfunction.
Article content
About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
6 hours ago
- CTV News
Premier defends charging most Albertans for COVID-19 vaccines
Alberta has announced COVID-19 vaccines will only be provided for free to certain members of the population starting this fall.
CBC
13 hours ago
- CBC
Alberta government to increase prescription costs for seniors for first time in 31 years
Social Sharing For the first time in more than three decades, the Alberta government is raising prescription costs for some seniors and Albertans under non-group coverage. Beginning July 1, the maximum co-payment per prescription will gradually increase by $10 over 10 months, from $25 to $35 at a rate of $1 per month. The increase will be fully implemented by April 1, 2026. It's the first time the cost has increased since 1994. Alberta seniors face rising drug prescription costs 2 days ago Duration 2:32 The province is raising out-of-pocket prescription costs for seniors and Albertans under non-group coverage by $10. According to the government, the hike is necessary to keep pace with a seven per cent annual increase in funding for these programs. The province says the hike is necessary to keep pace with rising costs, with the cost of providing coverage for seniors and those in the non-group program increasing by about seven per cent annually. The majority of Alberta seniors will still pay less than seniors in most other provinces, the province said. But for seniors like Marilyn Wieler, 83, the added expense represents more than a minor adjustment. "It's a hardship, people weren't prepared for this. And why the seniors?" Said Wieler, a volunteer at the Mill Woods Seniors and Multicultural Centre. "We're on a limited income. Nobody's giving us extra money, and now they hit us with this. "When you really need it a lot of people can't afford it. That's really unjust." Alberta's non-group coverage provides prescription drug insurance to residents under 65 who aren't covered by an employer or private plan. If the co-payments increased at the same rate of inflation, seniors would be paying $48, according to the government. "The cost to provide this coverage is rising significantly due to factors such as increasing drug prices, population growth, and an aging population. To maintain the long-term sustainability of these programs and keep medications accessible, an increase to the maximum co-payment for seniors is necessary," said the office of the minister of Primary and Preventative Health Services in a statement to CBC. Change adds stress, advocates say Currently, there are about 760,000 Albertans aged 65 and older that have senior drug coverage, though only about five per cent pay the maximum co-payment, the province said. Among the roughly 75,000 Albertans with non-group coverage, about 18 per cent hit the maximum. Low-income seniors can apply for assistance through the province's special needs assistance for seniors program, the province said. Still, advocates and seniors say the change adds stress, especially for those managing multiple prescriptions. "We know that means some people won't access the medications they need. They'll end up sicker, they'll end up in our hospital system and it'll cost us more. That's the story of drugs," said Chris Gallaway, the executive director at Friends of Medicare. "Affordability is a big concern for seniors and everyone, but especially seniors on a fixed income. And by doing something like this, we know it means people won't be able to access the drugs they need. And it means that Albertans will be paying more and more out of pocket for healthcare that should be covered," he said. Rosemary Anderson, another senior at the Millwoods Centre, said she worries about the impact on low-income people. "You choose not to take your diabetic, you choose not to take your blood pressure because you can't afford it" "For wealthy people, $10 is nothing a month, but for a lot of people it is." The cost of administering the seniors and non-group drug programs in 2023-24 was around $1.3 billion. That figure is projected to rise by $194 million to approximately $1.494 billion by 2026-27. The number of seniors in Alberta is expected to nearly double to 1.4 million by 2051. In a statement, Sarah Hoffman, the Opposition health critic, criticized the move. "Because this increase is per prescription, more seniors will be forced into making a choice – medicine or food, or rent, or insurance, or utilities bills, all of which have increased in cost due to this incompetent and cruel UCP government," Hoffman said. "In the end senior's health will suffer, they will need more care because they can't afford medication, and the added strain on the entire health-care system will impact all Albertans."
CTV News
a day ago
- CTV News
CTV National News: Surgery wait times still behind pre-pandemic levels in Canada
Five years after COVID-19 began, wait times for cancer surgeries and joint replacements remain high despite increased procedures. CTV's Sarah Plowman reports.
